Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbViePublished : Friday, December 19, 2014
Galapagos NV announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (e.g., G551D). In combination with corrector GLPG2222, this potentiator will also be developed for patients affected by the F508del mutation, the most prevalent mutation in CF patients. This achievement triggers a milestone payment of $10 million from AbbVie.
Galapagos NV announced that it nominated a first pre-clinical candidate corrector GLPG2222 for clinical development in its cystic fibrosis (CF) program. This corrector, in combination with GLPG1837, forms the core of Galapagos' future combination therapy for the most common mutation in cystic fibrosis. The Galapagos combination has shown higher efficacy in pre-clinical studies than other therapies currently under clinical development.
During the symposium The Longevity Revolution it was announced that prof. dr. Joris Slaets, Professor of Geriatric Medicine at the University Medical Center Groningen, will join the board of Leyden Academy on Vitality and Ageing. He replaces prof. dr. Rudi Westendorp who will start as Professor of Medicine at Old Age at the University of Copenhagen on January 1.
> Read more in Dutch
Medical Delta the Co-Location Centre for the Netherlands and Belgium InnoLife, a consortium of 144 European companies, research institutes and universities, has been selected by the European Institute of Innovation and Technology (EIT) as the Knowledge and Innovation Community (KIC) for EIT Health. With a total volume of EUR 2.1 billion it is one of the largest public funded initiatives for health worldwide.
Thursday 22 January 2015 the second edition of Leiden Bio Science Park New Year’s reception will take place in ‘De Stal’, Darwinweg 1, Leiden. People working at Leiden Bio Science Park are invited to join. The reception starts at 18.00, following the Life Sciences Café, and ends at 22.30 at the latest. Registration is required!
Leiden University and Leiden University Medical Center (LUMC) are seeking commercial partners for collaborative development or licensing on a number of innovative technologies. Luris is the Knowledge Exchange office for both organisations. Luris represents the interests of academics while at the same time helping societal partners, industry and users of Leiden research and technology to become more successful and enhance Leiden’s impact on the world.
December 2 the Hayabusa2 spacecraft has been successfully launched. Hayabusa2 is now on its way to asteroid 1999 JU3 and is expected to arrive in 2018, and will then send its Mobile Asteroid Surface Scout (MASCOT) to the surface. The spacecraft is reported to operate nominally, so we look forward to seeing our sensors in action during the landing in 4 years from now!
Publication in Nature supports ISA Pharmaceuticals´ synthetic long peptide immunotherapeutic approach to treat cancerPublished : Thursday, November 27, 2014
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, announced that a recent scientific paper in Nature supports the company´s therapeutic approach to using synthetic long peptides in cancer therapy. It could be shown that personalized SLP® immunotherapy is as capable of inducing efficient tumor eradication as are T cell checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 monoclonal antibodies.
BioMarin Pharmaceutical Inc. and Prosensa Holding N.V. announced that they have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later than February 15, 2017, respectively.
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 2 study with GLPG0634 has been completed. The Darwin Phase 2B program is now fully recruited and will begin a series of topline readouts starting around end of the first quarter 2015.
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, announces that it will present data supporting the safe use and absence of drug-drug interactions of GLPG0634 (filgotinib) with drugs commonly prescribed for rheumatoid arthritis (RA) patients. In addition, Galapagos will show support for the dose selection in the Phase 2B DARWIN program and present the reversals of RA disease gene expression in patients treated with GLPG0634.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe